The FDA and IBS drug development

American Journal of Gastroenterology

Volumn 104, Issue 12, 2009, Pages 3106-

  Mangel, Allen W ^a  

^a RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

CONSTIPATION; DIARRHEA; DRUG INDUSTRY; DYSPEPSIA; FECES INCONTINENCE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTESTINE FUNCTION; IRRITABLE COLON; LETTER; PATIENT SELECTION; POLICY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ALPROSTADIL; CHLORIDE CHANNELS; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DRUG APPROVAL; DRUG EVALUATION; DYSPEPSIA; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WISCONSIN;

EID: 72949116164     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.445     Document Type: Letter

References (1)

1. Talley NJ. Green light from the FDA for new drug development in irritable bowel syndrome and functional dyspepsia. Am J Gastroenterol 2009;104:1339-1341